Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Opposes 'Harmful' Changes To EMA’s Access To Documents Policy

Executive Summary

The EU pharmaceutical industry has concerns about the European Medicines Agency’s proposal to grant extended access to documents on orphan designations and pediatric investigation plans under its revised access to documents policy. The changes would discourage innovation and lead to inadvertent disclosure of commercially sensitive data, companies claim.

You may also be interested in...

Court Decision Means Longer Wait For Clarity On EMA’s Access To Documents Policy

The EU court’s dismissal of appeals filed by the European Medicines Agency in cases relating to its access to documents policy means stakeholders will have to wait even longer to get legal clarity on the policy. One lawyer believes that the case could result in a broader definition of what constitutes commercially confidential information.

EMA Revises Access Policy To Clarify Which Corporate Records Are Public

The European Medicines Agency is inviting feedback on changes to its policy on access to documents to clarify that it also covers the agency’s corporate documents.

Industry Concerned Over EMA Plan To Make More PIP Information Public

The European Medicines Agency’s plan to publish details of the studies and measures it agrees with a drug developer for a pediatric investigation plan will help other companies in framing their future marketing authorization applications. But there are concerns that the agency's plan might result in the disclosure of commercially confidential information.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts